Raymond James & Associates’s Maravai LifeSciences MRVI Stock Holding History

Raymond James & Associates’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21,362	Closed	-$266K	–	3885
2023 Q2	$266K	Buy	21,362 +5,229	+32%	+$70.6K	﹤0.01%	3330
2023 Q1	$226K	Buy	+16,133	New	+$232K	﹤0.01%	3424
2022 Q4	–	Sell	-14,875	Closed	-$380K	–	4008
2022 Q3	$380K	Buy	+14,875	New	+$373K	﹤0.01%	3028
2021 Q4	–	Sell	-10,959	Closed	-$538K	–	4232
2021 Q3	$538K	Buy	10,959 +469	+4%	+$22.9K	﹤0.01%	3012
2021 Q2	$438K	Sell	10,490 -60	-0.6%	-$2.33K	﹤0.01%	3184
2021 Q1	$376K	Buy	+10,550	New	+$350K	﹤0.01%	3214

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Raymond James & Associates's MRVI Position: Q3 2023 in Review

Raymond James & Associates sold out of Maravai LifeSciences (MRVI) in Q3 2023, closing a stake of 21,362 shares — an estimated $266K sold.

Raymond James & Associates first reported a position in MRVI in Q1 2021 and held it in 6 quarters. The position peaked at $538K in Q3 2021. 204 funds tracked by Wall St. Rank hold MRVI as of Q3 2023.

Raymond James & Associates reported no remaining Maravai LifeSciences position as of Q3 2023 after selling out during the quarter.
Raymond James & Associates sold 21,362 Maravai LifeSciences shares in Q3 2023, an estimated $266K.
Raymond James & Associates first reported a position in Maravai LifeSciences in Q1 2021 and held it in 6 quarters.
Raymond James & Associates's Maravai LifeSciences position peaked at $538K in Q3 2021.
204 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.